Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   HEPATITIS MONTHLY   APRIL 2014 , Volume 14 , Number 4; Page(s) 0 To 0.
 
Paper: 

ASSOCIATION OF PROTON PUMP INHIBITOR THERAPY WITH HEPATIC ENCEPHALOPATHY IN HEPATITIS B VIRUS-RELATED ACUTE-ON-CHRONIC LIVER FAILURE

 
 
Author(s):  LIN ZHAO NI, ZUO YONG QING, HU PENG*
 
* DEPARTMENT OF INFECTIOUS DISEASES, INSTITUTE FOR VIRAL HEPATITIS, KEY LABORATORY OF MOLECULAR BIOLOGY FOR INFECTIOUS DISEASES, MINISTRY OF EDUCATION, SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY, CHONGQING, CHINA
 
Abstract: 

Background: Hepatic encephalopathy (HE) is an important neuropsychiatry complication of acute-on-chronic liver failure (ACLF). PPI therapy may increase the intestinal bacterial overgrowth and infections.
Objectives: The aim of this study was to assess whether PPI use in ACLF is associated with HE.
Patients and Methods: A retrospective case-control study was performed. Fifty five admitted patients with hepatitis B virus (HBV) -related ACLF complicated by Stage II-IV HE developed after admission between January 2008 and December 2012 were matched (by sex, age, and MELD score) with comparable HBV-related ACLF patients (n=110) who did not develop this complication during hospitalization. We excluded combined HE upon admission and other neurological disorders in patients with ACLF. Univariate and multivariate analyses of 30 variables (laboratory examination, predisposition, treatment, etc.) before the occurrence of HE were carried out to identify the factors predictive of HE.
Results: In univariate analysis, patients with HE in ACLF had a significantly higher rate of PPI use (89.1%) compared with non-HE (63.6%, P=0.001). In addition, clinical and standard laboratory variables were significantly different between the two groups regarding the infection rate, hyponatremia, alpha-fetoprotein (AFP), Arginine Hydrochloride use and Lactulose use. Logistic regression analysis was used to examine the combined effects of the variables with HE as the outcome. HE in ACLF was associated with hyponatremia (odds ratio (OR) =6.318, 95% confidence interval (CI) =2.803-14.241; P=0.000), PPI use was independently associated with HE (OR=4.392, CI=1.604-12.031; P=0.004), and lactulose use was protective (OR=0.294, CI=0.136-0.675; P=0.003).
Conclusions: The occurrence of HE is associated with hyponatremia and PPI use in patients with ACLF.

 
Keyword(s): HEPATIC ENCEPHALOPATHY, PROTON PUMP INHIBITORS, HEPATITIS B VIRUS
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

LIN, Z., & ZUO, Y., & HU, P. (2014). ASSOCIATION OF PROTON PUMP INHIBITOR THERAPY WITH HEPATIC ENCEPHALOPATHY IN HEPATITIS B VIRUS-RELATED ACUTE-ON-CHRONIC LIVER FAILURE. HEPATITIS MONTHLY, 14(4), 0-0. https://www.sid.ir/en/journal/ViewPaper.aspx?id=411041



Vancouver: Copy

LIN ZHAO NI, ZUO YONG QING, HU PENG. ASSOCIATION OF PROTON PUMP INHIBITOR THERAPY WITH HEPATIC ENCEPHALOPATHY IN HEPATITIS B VIRUS-RELATED ACUTE-ON-CHRONIC LIVER FAILURE. HEPATITIS MONTHLY. 2014 [cited 2021October16];14(4):0-0. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=411041



IEEE: Copy

LIN, Z., ZUO, Y., HU, P., 2014. ASSOCIATION OF PROTON PUMP INHIBITOR THERAPY WITH HEPATIC ENCEPHALOPATHY IN HEPATITIS B VIRUS-RELATED ACUTE-ON-CHRONIC LIVER FAILURE. HEPATITIS MONTHLY, [online] 14(4), pp.0-0. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=411041.



 
  pdf-File
Yearly Visit 35
 
 
Latest on Blog
Enter SID Blog